NCT02230176View on ClinicalTrials.gov

Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II

PHASE2CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

April 30, 2024

Study Completion Date

April 30, 2024

Conditions
Pancreatic Neuroendocrine Carcinoma
Interventions
DRUG

Sunitinib

DRUG

177Lu-DOTA0-Tyr3-Octreotate

Trial Locations (1)

94805

Gustave Roussy, Villejuif

Sponsors
All Listed Sponsors
collaborator

National Cancer Institute, France

OTHER_GOV

collaborator

Advanced Accelerator Applications

INDUSTRY

lead

Gustave Roussy, Cancer Campus, Grand Paris

OTHER